Shred Injectable (T3 Liothyronine Sodium + SR-9011 + Yohimbine)

Shred is composed of T3 Liothyronine, SR-9011, and Yohimbine.
Shred Injectable is offered in a 10ml/100mg per ml/1g formulation, containing 33.3mg per ml of T3 Liothyronine, 33.3mg per ml of SR-9011, and 33.3mg per ml of Yohimbine.

Shred Injectable is a product that combines T3 Liothyronine Sodium, SR-9011, and Yohimbine to explore potential synergies among these compounds. T3 Liothyronine Sodium, recognized for its influence on thyroid function and metabolism, is combined with SR-9011, an agonist of REV-ERB, believed to impact circadian rhythm and metabolic processes. Yohimbine, functioning as an alpha-2 adrenergic receptor antagonist, may affect various physiological functions, including blood flow and fat metabolism. The coalescence of T3 Liothyronine Sodium, SR-9011, and Yohimbine within Shred provides researchers with an avenue to investigate their collective impact on metabolism, energy regulation, and potential fat loss.

T3 Liothyronine Sodium
CAS Number	6893-02-3
Molar Mass	650,9735 g/mol
Chemical Formula	C15H12I3NO4
IUPAC Name	sodium;(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate

SR-9011
CAS Number	1379686-29-9
Molar Mass	479.04 g·mol−1
Chemical Formula	C23H31ClN4O3S
IUPAC Name	3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]-N-pentylpyrrolidine-1-carboxamide

Yohimbine
CAS Number	146-48-5
Molar Mass	354.450 g·mol−1
Chemical Formula	C21H26N2O3
IUPAC Name	17α-hydroxy-yohimban-16α- carboxylic acid methyl ester